Peritoneal cfDNA and RFS
tumor, CRC
TUMOR, TUMOR RECURRENCE, POSITIVE
To clarify the prognostic value of peritoneal cfDNA in CRC patients without PM, 23 CRC patients in the non-PM were followed-up from the date of surgery until tumor recurrence or until Aug 31, 2022 for patients without tumor relapse. The FLD cfDNA was sampled at the aspiration of peritoneal fluid during the surgery. The median follow-up time was 13.8 months (range: 0.8–18.6 months). Positive peritoneal cfDNA was associated with tumor recurrence (